Experience of Autologous Stem Cell Transplant in Multiple Myeloma: The Patient and Caregiver Perspective
- PMID: 37766811
- PMCID: PMC10521273
- DOI: 10.1177/23743735231202733
Experience of Autologous Stem Cell Transplant in Multiple Myeloma: The Patient and Caregiver Perspective
Abstract
A qualitative study of the experiences of patients who received autologous stem cell transplant (ASCT) for the treatment of multiple myeloma (MM) was conducted to better understand their MM disease journey, including first symptoms, diagnosis, ASCT, and recovery. Sixteen participants, including 12 patients with MM and 4 caregivers of patients with MM, were interviewed in focus group meetings. Pain, weakness, and bone pain were common first symptoms among patients. The MM diagnosis was often made by a hematologist or oncologist. Patients were referred to a specialized oncologist after diagnosis, who was the primary driver in making ASCT treatment decisions. Eight patients received their ASCT in the inpatient setting, with some having lengthy hospital stays; 4 received their ASCT in an outpatient setting with 3 eventually being hospitalized. The focus groups identified that patients and caregivers perceived various unmet needs and impacts on quality of life throughout their transplant journey. Educational resources and innovative therapies are needed to reduce the disease burden of MM and enhance the quality of life for both patients and their caregivers.
Keywords: autologous stem cell transplant; disease journey; focus group; multiple myeloma; patient experience.
© The Author(s) 2023.
Conflict of interest statement
DKH has consulted with BMS, Karyopharm, Janssen, and Pfizer; received research funding from BMS, the International Myeloma Society, Karyopharm, and the Pentecost Family Myeloma Research Center; received honoraria from OncLive and Survivorship; and served on BMS IMW Ide-celacademic advisory board, BMS MM ASH Steering Committee, and MM Pfizer Advisory Board. TB, KF, LS, KB, Y-HL, and SH are employees of Janssen Scientific Affairs, LLC, and hold Johnson & Johnson stock. CB works for CorEvitas, which provided analytical services funded by Janssen Pharmaceuticals.
Figures
Similar articles
-
Risk of febrile neutropenia among patients with multiple myeloma or lymphoma who undergo inpatient versus outpatient autologous stem cell transplantation: a systematic review and meta-analysis.BMC Cancer. 2018 Nov 16;18(1):1126. doi: 10.1186/s12885-018-5054-6. BMC Cancer. 2018. PMID: 30445930 Free PMC article.
-
The Burden in Caregivers of Multiple Myeloma Patients Undergoing Outpatient Autologous Stem-Cell Transplantation Compared to Inpatient Transplantation.Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):e402-e409. doi: 10.1016/j.clml.2020.11.011. Epub 2020 Nov 20. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33288484
-
Characterizing the Patient Journey in Multiple Myeloma: Qualitative Review.JMIR Cancer. 2022 Sep 22;8(3):e39068. doi: 10.2196/39068. JMIR Cancer. 2022. PMID: 36136395 Free PMC article. Review.
-
Trajectory of Symptoms in Patients Undergoing Autologous Stem Cell Transplant for Multiple Myeloma: A Population-Based Cohort Study of Patient-Reported Outcomes.Clin Lymphoma Myeloma Leuk. 2021 Sep;21(9):e714-e721. doi: 10.1016/j.clml.2021.05.002. Epub 2021 May 9. Clin Lymphoma Myeloma Leuk. 2021. PMID: 34099429
-
Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.Ann Hematol. 2018 Oct;97(10):1869-1877. doi: 10.1007/s00277-018-3370-1. Epub 2018 May 21. Ann Hematol. 2018. PMID: 29781040
Cited by
-
Patient and caregiver perspectives on treatment decision-making for stem cell transplantation in multiple myeloma.Support Care Cancer. 2025 Jan 31;33(2):134. doi: 10.1007/s00520-025-09195-1. Support Care Cancer. 2025. PMID: 39890679
References
-
- American Cancer Society. Key statistics about multiple myeloma. Available at: https://www.cancer.org/cancer/multiple-myeloma/about/key-statistics.html. Accessed January 25, 2023.
-
- Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma. JAMA. 2022;327:464‐77. - PubMed
LinkOut - more resources
Full Text Sources